渤健Biogen (BIIB) 2003年年度报告「NASDAQ」.pdf

1、2003Biogen Idecannual report a human face .Robin Sherrill,AVONEX patientW human concerntherapies are born from .Basav Ghosh,Manager,Cell CultureDevelopment,Research Triangle Park,NC annual reportOExcellence scientific discoveries lead to .Meena Subramanyam,Ph.D.,Director,Clinical Science&Technology,

2、Cambridge,MA annual reportW manufacturingto develop and the capacity .Jack Giese,Associate DirectorManufacturing NIMO,Oceanside,CA annual reportBiogen Idec was born of a partnership.The idea of partnership is central to our company:partnership with patients and caregivers,partnership among employees

3、 and with the community,and partnership with others within our industry.As webuild our company,realizing the full potential of our combined resources and strengths,partnership and collaboration willremain key factors in Biogen Idecs success.W .Please keep in mind that every individual experiences th

4、erapy with RITUXAN,AVONEX,AMEVIVE and ZEVALIN differently.A patients own experience may be different than the ones highlighted in this document.annual reportBen BakerinkCancer survivor and employeeRITUXAN in Combination with Chemotherapy :In April 1999,information technology specialist Ben Bakerink

5、went to see his doctor about a hernia.Instead,he received thediagnosis of low-grade non-Hodgkins lymphoma.At the time,Ben says,few treatment options were available.RITUXAN(rituximab)had recently been approved to treat relapsed or refractory,low-grade or follicular,CD20-positive non-Hodgkins B-cell l

6、ymphoma.Bensoncologist who had participated in clinical trials with RITUXAN suggested treatment with the newly approved therapy in combina-tion with CHOP,a chemotherapy regimen consisting of cyclophosphamide,doxorubicin,vincristine and prednisone.The chemotherapyleft Ben tired and weak.But by the en